Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.047
Buy
RSI(14)
53.936
Neutral
STOCH(KDJ)(9,3,3)
18.738
Neutral
ATR(14)
0.405
High Vlolatility
CCI(14)
32.478
Neutral
Williams %R
73.516
Sell
TRIX(12,20)
0.401
Sell
StochRSI(14)
54.432
Neutral
Search
Cellectar Biosciences Inc
CLRBAdd to Watchlist
3.090USD
-0.110-3.44%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
24.69MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Cellectar Biosciences Inc
Currency: USD Updated: 2026-05-15Key Insights
Cellectar Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 80 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 10.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cellectar Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Cellectar Biosciences Inc Highlights
StrengthsRisks
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
Undervalued
The company’s latest PE is -0.57, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 366.56K shares, decreasing 44.16% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 10.46.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
10.500
Target Price
+228.13%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Cellectar Biosciences Inc is 7.19, ranking 117 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.18
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Cellectar Biosciences Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Cellectar Biosciences Inc is 8.85, ranking 4 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -0.57, which is -127.62% below the recent high of 0.16 and -39.11% above the recent low of -0.80.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 80/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Cellectar Biosciences Inc is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 47.00, with a high of 76.00 and a low of 18.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
10.500
Target Price
+228.13%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Cellectar Biosciences Inc
CLRB
2
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Cellectar Biosciences Inc is 7.05, ranking 57 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.36 and the support level at 2.17, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.042
Buy
MA10
3.115
Sell
MA20
2.919
Buy
MA50
2.918
Buy
MA100
3.079
Buy
MA200
3.689
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Cellectar Biosciences Inc is 3.00, ranking 94 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 6.26%, representing a quarter-over-quarter decrease of 38.18%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Cellectar Biosciences Inc. The Pharmaceuticals industry's average is 5.23. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.49
VaR
+7.69%
240-Day Maximum Drawdown
+81.95%
240-Day Volatility
+133.63%
Return
Best Daily Return
60 days
+12.37%
120 days
+23.38%
5 years
+66.32%
Worst Daily Return
60 days
-10.37%
120 days
-13.84%
5 years
-76.56%
Sharpe Ratio
60 days
+0.29
120 days
+0.61
5 years
-0.46
Risk Assessment
Maximum Drawdown
240 days
+81.95%
3 years
+94.46%
5 years
+97.78%
Return-to-Drawdown Ratio
240 days
-0.74
3 years
+0.18
5 years
-0.14
Skewness
240 days
+2.69
3 years
-0.53
5 years
-0.33
Volatility
Realised Volatility
240 days
+133.63%
5 years
+195.62%
Standardised True Range
240 days
+15.44%
5 years
+10.07%
Downside Risk-Adjusted Return
120 days
+120.04%
240 days
+120.04%
Maximum Daily Upside Volatility
60 days
+143.01%
Maximum Daily Downside Volatility
60 days
+62.14%
Liquidity
Average Turnover Rate
60 days
+63.86%
120 days
+34.26%
5 years
--
Turnover Deviation
20 days
+1047.11%
60 days
+304.34%
120 days
+116.92%
Peer Comparison
Pharmaceuticals
Cellectar Biosciences Inc
CLRB
6.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
